ENvue Medical unveils robotic prototype combining AI navigation with automated tube placement

Envue Medical Expands AI Navigation Platform With Robotic Prototype - ENvue Medical (NASDAQ:FEED)

ENvue Medical, Inc. (NASDAQ:FEED) announced Thursday the development and demonstration of the prototype of ENvue Drive. It is an investigational robot-assisted platform designed to combine artificial intelligence, real-time electromagnetic navigation, and robotic-assisted procedural execution into a single bedside workflow. Prototype Combines AI, Navigation And Robotics The company said the prototype marks a key milestone in its strategy to integrate navigation, AI, and automation into clinical procedures. The prototype demonstration paired ENvue's proprietary AI navigation software, Ask Oscar, with robotic-assisted tube advancement to simulate a bedside enteral feeding tube placement procedure. According to the company, ENvue Drive identified anatomical pathways, detected deviations from the intended trajectory, provided corrective guidance, and assisted with advancing the feeding tube to the target location in the small intestine under clinician supervision. ENvue emphasized that the system is designed to support clinicians rather than replace them, with the healthcare professional maintaining full control throughout the procedure. Built On Existing Navigation Platform The company said ENvue Drive is being developed on its 510(k) FDA-cleared ENvue Navigation Platform, which is currently used in hospitals across the U.S. for real-time electromagnetic guidance during enteral feeding tube placement. ENvue recently introduced Ask Oscar, its AI-based education and training platform, and said it is now expanding that technology to support future procedural guidance and robotic-assisted execution. Platform Designed For Future Clinical Applications ENvue said the platform architecture was designed from the outset to support both enteral and vascular access procedures, consistent with its previously announced 2025 initiative. ENvue noted that ENvue Drive remains an investigational prototype and has not been submitted to the U.S. Food and Drug Administration for review. The system has not been cleared or approved for clinical use. FEED Stock Price Activity: ENvue Medical shares were up 4.82% at $0.49 during premarket trading on Thursday, according to Benzinga Pro data. Image via Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

ENvue Medical demonstrates robotic feeding tube prototype By Investing.com

TYLER, Texas - ENvue Medical, Inc. (NASDAQ:FEED) announced today the development and demonstration of a prototype for ENvue Drive, a robotic-assisted tool designed for bedside feeding tube placement procedures. The prototype integrates the company's AI navigation software, Ask Oscar, with robotic-assisted tube advancement to replicate a bedside enteral access procedure, according to a press release statement. The demonstration showed the device can identify anatomical pathways, detect trajectory deviations, provide corrective guidance, and assist advancement to a target position within the small intestine under clinician supervision. ENvue Drive is built on the company's FDA 510(k)-cleared ENvue Navigation Platform, which provides electromagnetic guidance during enteral feeding tube placement in U.S. hospitals. The device is designed to assist clinicians who retain full control of procedures at all times. The company stated the prototype was designed as a platform architecture intended to support both enteral and vascular access procedures. The current demonstration focused on enteral tube advancement, with vascular access, neonatal care, and urinary access representing potential future applications. ENvue Drive is an investigational prototype that has not been submitted to the U.S. Food and Drug Administration and is not cleared or approved for clinical use. The company indicated it is targeting what it describes as a combined enteral feeding and vascular access market opportunity exceeding $10 billion, citing market research from Grand View Research and MarketsandMarkets. Despite this ambitious market vision, ENvue Medical currently trades at a market capitalization of just $2.91 million with a stock price of $0.48, down 95% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with shares trading near their 52-week low. Investors can access the complete Most Undervalued stocks list and 16 additional ProTips for FEED on the platform. ENvue Medical is a commercial-stage medical device company headquartered in Tyler, Texas, with research and development operations in Tel-Aviv and Nesher, Israel. The company specializes in electromagnetic navigation systems for feeding tube placement and acoustic-based therapeutic technologies. In other recent news, ENvue Medical announced the renewal of a three-year contract with a nonprofit health system operating 12 hospitals across Virginia and North Carolina. The contract ensures that the ENvue Navigation Platform remains the standardized protocol for bedside enteral feeding tube placement through 2028. Additionally, ENvue Medical received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a drug delivery system using surface acoustic wave technology to enhance transdermal delivery of cannabinoid-based therapeutics. The company also introduced Ask Oscar, an AI-powered training platform that allows healthcare professionals to train independently on feeding tube placement. Furthermore, ENvue Medical reported that a major U.S. academic health network has deployed a second ENvue Navigation Platform in its burn intensive care unit. A peer-reviewed study published in Critical Care Nurse highlighted operational improvements at Inova Health System after adopting ENvue's feeding tube placement technology, noting reduced complications. These developments represent significant strides for ENvue Medical in expanding its technology and services in the healthcare sector. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.